Related Experiment Video
Updated: Jul 16, 2026
A Rat Model of Ventricular Fibrillation and Resuscitation by Conventional Closed-chest Technique
Published on: April 26, 2015
Efficacy of carvedilol on complex ventricular arrhythmias in dilated cardiomyopathy: double-blind, randomized,
G Cice1, E Tagliamonte, L Ferrara
1Institute of Cardiovascular Clinic and Surgery, Division of Cardiology, Second University of Naples, Italy.
Insights
Adding carvedilol to standard therapy benefits patients with dilated cardiomyopathy and complex ventricular arrhythmias. This treatment improves heart function and reduces arrhythmia episodes, offering a valuable therapeutic option.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Dilated cardiomyopathy (DCM) is a significant cause of heart failure.
- Complex ventricular arrhythmias pose a serious risk in DCM patients.
- Conventional therapy may not fully address arrhythmic complications.
Purpose of the Study:
- To evaluate the efficacy of carvedilol in treating complex ventricular arrhythmias in DCM patients.
- To determine if carvedilol offers additional benefits beyond conventional therapy.
Main Methods:
- 168 DCM patients with complex ventricular arrhythmias were recruited.
- Patients received either carvedilol or placebo for 6 months.
- Ventricular function and arrhythmic episodes were monitored.
Main Results:
- Carvedilol improved ventricular function and reduced arrhythmia incidence.
- Initial antiarrhythmic effects were more pronounced in ischemic DCM, attributed to carvedilol's anti-ischemic properties.
- After 3 months, ejection fraction improved in all treated patients, with similar antiarrhythmic efficacy across etiologies.
Conclusions:
- Carvedilol's antiarrhythmic efficacy correlates with ejection fraction improvement, irrespective of heart failure cause.
- Adding carvedilol is a viable therapeutic strategy for reducing complex ventricular arrhythmias in DCM.
- This approach should be considered in optimizing DCM patient management.
Aims:
The aim of the present study was to investigate whether the addition of carvedilol to conventional therapy in dilated cardiomyopathy patients is associated with further benefits in the treatment of complex non-sustained ventricular arrhythmias (Lown class III, IV or V).
Methods And Results:
We recruited 168 patients with ischaemic or idiopathic dilated cardiomyopathy, with complex ventricular arrhythmias. Patients able to tolerate low doses of carvedilol were randomized to treatment with carvedilol or placebo for 6 months. Carvedilol treatment improved ventricular function and reduced the incidence of arrhythmic episodes. Notably, by the end of the first month of treatment, the antiarrhythmic efficacy of the drug was significantly greater in patients with ischaemic than in those with idiopathic dilated cardiomyopathy, an effect that could probably be attributed to the anti-ischaemic properties of carvedilol. After 3 months, at a time when ejection fraction was significantly improved in all treated patients, the antiarrhythmic efficacy of carvedilol was similar in the two study groups.
Conclusions:
Carvedilol antiarrhythmic efficacy was paralleled by the improvement in ejection fraction, independent of the aetiology of heart failure. The possibility of adding to an already 'optimized' conventional therapy a drug able to reduce the incidence of complex non-sustained ventricular arrhythmias is a therapeutic option that should be considered in the treatment of these patients.
More Related Videos
10:05Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
Published on: July 7, 2016
12:45Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
Related Concept Videos
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:22Heart Failure Drugs: β-Blockers
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:30Cardiomyopathy II: Dilated Cardiomyopathy